Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    50,771.48
    +575.78 (+1.15%)
     

  • CMC Crypto 200

    1,325.71
    +48.73 (+3.82%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

GSK agrees 700 mln stg sale of thrombosis treatments

Reuters - UK Focus

LONDON, Sept 30 (Reuters) - British pharmaceutical firm GlaxoSmithKline (LSE: GSK.L - news) (GSK) said on Monday it agreed to sell its thrombosis treatment brands and related manufacturing facility to South Africa's Aspen for 700 million pounds ($1.13 billion).

The company said the divestment, which will earn it proceeds of 600 million pounds, was part of its stragtegy to focus on products with the most growth potential.

GSK owns an 18.6 percent stake in Aspen, South Africa's biggest generic drug maker.